Dianthus Therapeutics released interim responder analysis data from the first 40 patients in Part A of the Phase 3 CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The trial observed a 75% responder rate among the first 40 participants. Based on these results, the company reached an early 'GO' decision to continue the trial with a modified design. The company maintains a strong financial position with approximately $1.2 billion in cash and investments as of March 31, 2026, with runway expected into 2030.